Paul Dent

List of Publications by Year in Descending Order

157 papers	11,905 citations	48 h-index	108 g-index
168 ext. papers	13,120 ext. citations	5.9 avg, IF	5.79 L-index

#	Paper	IF	Citations
157	GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells.. *Oncotarget*, **2022**, 13, 92-104	3.3	1
156	GZ17-6.02 and axitinib interact to kill renal carcinoma cells.. *Oncotarget*, **2022**, 13, 281-290	3.3	1
155	GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells. *Frontiers in Oncology*, **2021**, 11, 656453	5.3	2
154	Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43. *Aging*, **2021**, 13, 17097-17117	5.6	2
153	Chemotherapy resistance and YY1 **2021**, 243-249		
152	GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins. *Frontiers in Oncology*, **2021**, 11, 711043	5.3	2
151	Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. *Biochemical Pharmacology*, **2021**, 190, 114642	6	3
150	The development of multi-kinase inhibitors as pancreatic cancer therapeutics. *Anti-Cancer Drugs*, **2021**, 32, 779-785	2.4	1
149	Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells. *Frontiers in Oncology*, **2021**, 11, 723966	5.3	1
148	A novel plant-derived compound is synergistic with 5-fluorouracil and has increased apoptotic activity through autophagy in the treatment of actinic keratoses. *Journal of Dermatological Treatment*, **2020**, 1-2	2.8	5
147	Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer. *Biochemical Pharmacology*, **2020**, 178, 114067	6	9
146	Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]. *Cellular Signalling*, **2020**, 68, 109525	4.9	4
145	The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells. *Cellular Signalling*, **2020**, 70, 109573	4.9	10
144	Fingolimod Augments Monomethylfumarate Killing of GBM Cells. *Frontiers in Oncology*, **2020**, 10, 22	5.3	4
143	GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy. *Journal of Cellular Physiology*, **2020**, 235, 8098-8113	7	10
142	(Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo. *Journal of Cellular Physiology*, **2020**, 235, 6862-6874	7	16
141	Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies. *Immunometabolism*, **2020**, 2,	4.1	2

140	Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling. *Journal of Cellular Physiology*, **2020**, 235, 7889-7899	7	17
139	AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication. *Biochemical Pharmacology*, **2020**, 182, 114227	6	19
138	GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling. *Frontiers in Oncology*, **2020**, 10, 1331	5.3	5
137	The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib. *Seminars in Cancer Biology*, **2020**, 66, 129-139	12.7	21
136	Signaling alterations caused by drugs and autophagy. *Cellular Signalling*, **2019**, 64, 109416	4.9	15
135	Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody. *Cancer Biology and Therapy*, **2019**, 20, 109-121	4.6	13
134	The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib. *Frontiers in Oncology*, **2019**, 9, 650	5.3	9
133	Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. *Oncogene*, **2019**, 38, 5890-5904	9.2	40
132	Not the comfy chair! Cancer drugs that act against multiple active sites. *Expert Opinion on Therapeutic Targets*, **2019**, 23, 893-901	6.4	10
131	Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2019**, 42, 649-654	2.7	11
130	Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer. *Expert Opinion on Investigational Drugs*, **2019**, 28, 1095-1100	5.9	26
129	Neratinib augments the lethality of [regorafenib + sildenafil]. *Journal of Cellular Physiology*, **2019**, 234, 4874-4887	7	24
128	Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition. *Cancer Biology and Therapy*, **2019**, 20, 157-168	4.6	7
127	Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, G□and G□and kill uveal melanoma cells. *Cancer Biology and Therapy*, **2019**, 20, 700-710	4.6	23
126	Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition. *Cancer Biology and Therapy*, **2019**, 20, 597-607	4.6	5
125	Kinase inhibitors: look beyond the label on the bottle. **2019**, 2, 1032-1043		
124	The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. *Cancer Biology and Therapy*, **2018**, 19, 132-137	4.6	25
123	The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. *Cancer Biology and Therapy*, **2018**, 19, 239-247	4.6	4

122	The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells. *Cancer Biology and Therapy*, **2018**, 19, 525-533	4.6	14
121	TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition. *Autophagy*, **2018**, 14, 942-957	10.2	24
120	NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells **2018**, 1, 19-30		7
119	The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells. *Cancer Biology and Therapy*, **2018**, 19, 786-796	4.6	12
118	[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration. *Oncotarget*, **2018**, 9, 6062-6074	3.3	16
117	Valproate augments Niraparib killing of tumor cells. *Cancer Biology and Therapy*, **2018**, 19, 797-808	4.6	8
116	Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells. *Advances in Cancer Research*, **2018**, 137, 1-15	5.9	6
115	[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells. *Cancer Biology and Therapy*, **2017**, 18, 705-714	4.6	35
114	PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. *Oncotarget*, **2017**, 8, 1449-1468	3.3	37
113	PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. *Oncotarget*, **2017**, 8, 13464-13475	3.3	9
112	The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. *Oncotarget*, **2017**, 8, 16367-16386	3.3	42
111	HDAC inhibitors enhance the immunotherapy response of melanoma cells. *Oncotarget*, **2017**, 8, 83155-83170	3.3	81
110	HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody. *Oncotarget*, **2017**, 8, 90262-90277	3.3	42
109	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
108	Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. *Oncotarget*, **2016**, 7, 12975-96	3.3	35
107	The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. *Oncotarget*, **2016**, 7, 19620-30	3.3	40
106	Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS. *Oncotarget*, **2016**, 7, 17290-300	3.3	16
105	[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFB compensatory survival signaling. *Oncotarget*, **2016**, 7, 23608-32	3.3	25

104	Phase I study of pemetrexed with sorafenib in advanced solid tumors. *Oncotarget*, **2016**, 7, 42625-42638	3.3	6
103	Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo. *Oncotarget*, **2016**, 7, 40398-40417	3.3	17
102	Rationally Repurposing Ruxolitinib (Jakafi ( )) as a Solid Tumor Therapeutic. *Frontiers in Oncology*, **2016**, 6, 142	5.3	28
101	AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins. *Journal of Clinical & Cellular Immunology*, **2016**, 7,	2.7	6
100	Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95. *Oncotarget*, **2016**, 7, 4399-413	3.3	29
99	AR-12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication. *Journal of Cellular Physiology*, **2016**, 231, 2286-302	7	32
98	Reversing translational suppression and induction of toxicity in pancreatic cancer cells using a chemoprevention gene therapy approach. *Molecular Pharmacology*, **2015**, 87, 286-95	4.3	5
97	Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity. *Molecular Pharmacology*, **2015**, 88, 512-23	4.3	9
96	Nexavar/Stivarga and viagra interact to kill tumor cells. *Journal of Cellular Physiology*, **2015**, 230, 2281-98	7	37
95	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. *Carcinogenesis*, **2015**, 36 Suppl 1, S254-96	4.6	176
94	Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. *Carcinogenesis*, **2015**, 36 Suppl 1, S2-18	4.6	44
93	OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies. *Journal of Cellular Physiology*, **2015**, 230, 1982-98	7	34
92	Differential regulation of autophagy and cell viability by ceramide species. *Cancer Biology and Therapy*, **2015**, 16, 733-42	4.6	18
91	Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance. *Cancer Biology and Therapy*, **2015**, 16, 1660-70	4.6	17
90	GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases. *Journal of Cellular Physiology*, **2015**, 230, 2552-78	7	41
89	GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease. *Journal of Cellular Physiology*, **2015**, 230, 1661-76	7	63
88	The role of cell signalling in the crosstalk between autophagy and apoptosis. *Cellular Signalling*, **2014**, 26, 549-55	4.9	251
87	Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. *Molecular Pharmacology*, **2014**, 85, 408-19	4.3	56

86	Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs. *Molecular Cancer Therapeutics*, **2014**, 13, 2384-98	6.1	37
85	Not so WEE: targeting G2M to kill mesothelioma cells. *Cancer Biology and Therapy*, **2014**, 15, 351-2	4.6	1
84	New methods to control neuroblastoma growth. *Cancer Biology and Therapy*, **2014**, 15, 481-2	4.6	5
83	Pazopanib and HDAC inhibitors interact to kill sarcoma cells. *Cancer Biology and Therapy*, **2014**, 15, 578-85	4.6	31
82	Met in lung cancer. *Cancer Biology and Therapy*, **2014**, 15, 653-4	4.6	2
81	PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. *Cancer Biology and Therapy*, **2014**, 15, 758-67	4.6	41
80	Crosstalk between ERK, AKT, and cell survival. *Cancer Biology and Therapy*, **2014**, 15, 245-6	4.6	69
79	Non-canonical p53 signaling to promote invasion. *Cancer Biology and Therapy*, **2013**, 14, 879-80	4.6	6
78	PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. *Cancer Biology and Therapy*, **2013**, 14, 458-65	4.6	50
77	OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. *Cancer Biology and Therapy*, **2012**, 13, 224-36	4.6	39
76	Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. *Molecular Pharmacology*, **2012**, 82, 322-32	4.3	30
75	Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. *Cancer Biology and Therapy*, **2012**, 13, 567-74	4.6	21
74	Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. *Blood*, **2011**, 118, 5189-200	2.2	39
73	Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. *Cancer Research*, **2011**, 71, 4955-67	10.1	81
72	CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. *Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics*, **2011**, 11, 133-40		74
71	Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. *Molecular Cancer Therapeutics*, **2010**, 9, 2220-31	6.1	71
70	Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. *Cancer Research*, **2010**, 70, 6313-24	10.1	81
69	Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. *Journal of Biological Chemistry*, **2010**, 285, 10064-10077	5.4	52

68	Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells. *Molecular Pharmacology*, **2010**, 78, 909-17	4.3	33
67	Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. *Cancer Biology and Therapy*, **2010**, 10, 903-17	4.6	67
66	The development of MDA-7/IL-24 as a cancer therapeutic. *Pharmacology & Therapeutics*, **2010**, 128, 375-84	13.9	48
65	Minting a new class of polo-like-kinase inhibitors. *Cancer Biology and Therapy*, **2009**, 8, 2384-5	4.6	
64	PI3K: A rational target for ovarian cancer therapy?. *Cancer Biology and Therapy*, **2009**, 8, 27-30	4.6	7
63	BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. *Molecular Pharmacology*, **2009**, 76, 327-41	4.3	78
62	Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. *Cancer Research*, **2009**, 69, 143-50	10.1	250
61	Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. *Molecular Pharmacology*, **2009**, 76, 342-55	4.3	71
60	Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. *Drug Resistance Updates*, **2009**, 12, 65-73	23.2	37
59	Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism.. *Blood*, **2009**, 114, 297-297	2.2	2
58	Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo. *Cancer Biology and Therapy*, **2008**, 7, 587-93	4.6	3
57	Searching for a cure: gene therapy for glioblastoma. *Cancer Biology and Therapy*, **2008**, 7, 1335-40	4.6	15
56	Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. *Molecular Cancer Therapeutics*, **2008**, 7, 616-29	6.1	17
55	Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. *Clinical Cancer Research*, **2008**, 14, 5385-99	12.9	87
54	Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. *Cancer Biology and Therapy*, **2008**, 7, 1648-62	4.6	142
53	Radiation-induced cell signaling: inside-out and outside-in. *Molecular Cancer Therapeutics*, **2007**, 6, 789-801	6.1	272
52	The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. *Molecular Pharmacology*, **2007**, 72, 788-95	4.3	61
51	Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment. *Molecular Pharmacology*, **2007**, 71, 259-75	4.3	7

50	Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. *Molecular Cancer Therapeutics*, **2007**, 6, 3101-12	6.1	28
49	The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. *Molecular and Cellular Biology*, **2007**, 27, 5499-513	4.8	185
48	Vorinostat Synergistically Potentiates MK-0457 Lethality in Chronic Myelogenous Leukemia (CML) Cells Sensitive and Resistant to Imatinib Mesylate.. *Blood*, **2007**, 110, 1041-1041	2.2	3
47	Approaches for monitoring signal transduction changes in normal and cancer cells. *Methods in Molecular Biology*, **2007**, 383, 259-76	1.4	
46	Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells. *Molecular Pharmacology*, **2006**, 70, 1965-73	4.3	12
45	OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. *Molecular Pharmacology*, **2006**, 70, 589-603	4.3	74
44	Radiation-stimulated ERK1/2 and JNK1/2 signaling can promote cell cycle progression in human colon cancer cells. *Cell Cycle*, **2005**, 4, 456-64	4.7	19
43	DMC: novel celecoxib derivatives to rap cancer. *Cancer Biology and Therapy*, **2005**, 4, 583-4	4.6	2
42	Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. *Cancer Biology and Therapy*, **2005**, 4, 1275-84	4.6	18
41	Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms. *Gene*, **2005**, 350, 51-8	3.8	47
40	Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. *Blood*, **2005**, 105, 1706-16	2.2	59
39	Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. *Biochemical Pharmacology*, **2005**, 70, 1685-96	6	19
38	MDA-7/IL-24 regulates proliferation, invasion and tumor cell radiosensitivity: a new cancer therapy?. *Journal of Cellular Biochemistry*, **2005**, 95, 712-9	4.7	21
37	Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. *Hepatology*, **2005**, 42, 1291-9	11.2	100
36	H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. *Molecular Cancer Therapeutics*, **2005**, 4, 243-55	6.1	16
35	Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. *Molecular Cancer Therapeutics*, **2005**, 4, 257-70	6.1	57
34	Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. *Clinical Cancer Research*, **2004**, 10, 5724-31	12.9	53
33	Co-Administration of SAHA and 17-AAG Synergistically Induces Apoptosis in Bcr-Abl+ Cells Sensitive and Resistant to STI-571 in Association with Down-Regulation of Bcr-Abl, Abrogation of STAT5 Activity, and Bax Conformational Change.. *Blood*, **2004**, 104, 1995-1995	2.2	1

32	The regulation of tumor suppressor genes by oncogenes. *Methods in Molecular Biology*, **2003**, 222, 269-92	2.4	2
31	MAPK pathways in radiation responses. *Oncogene*, **2003**, 22, 5885-96	9.2	487
30	Stress and radiation-induced activation of multiple intracellular signaling pathways. *Radiation Research*, **2003**, 159, 283-300	3.1	407
29	Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. *Oncogene*, **2002**, 21, 4032-41	9.2	135
28	Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. *Cancer Biology and Therapy*, **2002**, 1, 243-53	4.6	43
27	Ribonucleotide reductase inhibition: regulation of the radiosensitive phenotype via NF kappa B and Bcl-2. *Cancer Biology and Therapy*, **2002**, 1, 546-7	4.6	2
26	Hepatitis B virus X protein increases expression of p21(Cip-1/WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression. *Hepatology*, **2001**, 34, 906-17	11.2	44
25	Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. *Oncogene*, **2001**, 20, 3266-80	9.2	111
24	Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. *Molecular Biology of the Cell*, **2001**, 12, 2629-45	3.5	201
23	AP-1 and C/EBP transcription factors contribute to mda-7 gene promoter activity during human melanoma differentiation. *Journal of Cellular Physiology*, **2000**, 185, 36-46	7	37
22	Regulation of mda-7 gene expression during human melanoma differentiation. *Oncogene*, **2000**, 19, 1362-8	9.2	49
21	AP-1 and C/EBP transcription factors contribute to mda-7 gene promoter activity during human melanoma differentiation **2000**, 185, 36		1
20	Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. *Molecular Biology of the Cell*, **1999**, 10, 2493-506	3.5	291
19	Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. *Oncogene*, **1999**, 18, 4756-66	9.2	112
18	Molecular mechanisms of radiation-induced accelerated repopulation. *Radiation Oncology Investigations*, **1999**, 7, 321-30		79
17	Genetic evidence that stress-activated p38 MAP kinase is necessary but not sufficient for UV activation of HIV gene expression. *Biochemistry*, **1999**, 38, 13055-62	3.2	23
16	Molecular mechanisms of radiation-induced accelerated repopulation **1999**, 7, 321		2
15	Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. *Oncogene*, **1998**, 16, 2787-96	9.2	135

14	Alpha-adrenergic inhibition of proliferation in HepG2 cells stably transfected with the alpha1B-adrenergic receptor through a p42MAPkinase/p21Cip1/WAF1-dependent pathway. *FEBS Letters*, **1998**, 436, 131-8	3.8	23
13	Effects of ethanol on mitogen-activated protein kinase and stress-activated protein kinase cascades in normal and regenerating liver. *Biochemical Journal*, **1998**, 334 (Pt 3), 669-76	3.8	102
12	Prolonged activation of the mitogen-activated protein kinase pathway promotes DNA synthesis in primary hepatocytes from p21Cip-1/WAF1-null mice, but not in hepatocytes from p16INK4a-null mice. *Biochemical Journal*, **1998**, 336 (Pt 3), 551-60	3.8	61
11	Positive and negative regulation of JNK1 by protein kinase C and p42(MAP kinase) in adult rat hepatocytes. *FEBS Letters*, **1997**, 412, 9-14	3.8	27
10	Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. *Molecular Pharmacology*, **1997**, 52, 935-47	4.3	133
9	Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells. *Oncogene*, **1997**, 15, 53-61	9.2	51
8	Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin. *Biochemical Journal*, **1996**, 314 (Pt 2), 401-4	3.8	41
7	Activation of Raf by ionizing radiation. *Nature*, **1996**, 382, 813-6	50.4	152
6	Reversal of Raf-1 activation by purified and membrane-associated protein phosphatases. *Science*, **1995**, 268, 1902-6	33.3	187
5	Ordered phosphorylation of p42mapk by MAP kinase kinase. *FEBS Letters*, **1992**, 306, 17-22	3.8	128
4	The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. *Nature*, **1990**, 348, 302-8	50.4	514
3	Targetting of protein phosphatase 1 to the sarcoplasmic reticulum of rabbit skeletal muscle by a protein that is very similar or identical to the G subunit that directs the enzyme to glycogen. *FEBS Journal*, **1990**, 189, 243-9		67
2	Identification of three in vivo phosphorylation sites on the glycogen-binding subunit of protein phosphatase 1 from rabbit skeletal muscle, and their response to adrenaline. *FEBS Letters*, **1990**, 259, 281-5	3.8	43
1	Multisite phosphorylation of the glycogen-binding subunit of protein phosphatase-1G by cyclic AMP-dependent protein kinase and glycogen synthase kinase-3. *FEBS Letters*, **1989**, 248, 67-72	3.8	60